drugset / Trial / NCT00307801

Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

NCT00307801 ↗

Phase 3 Completed 231 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.

Timeline

Start
2006-02
Primary completion
2008-05
Completion
2008-05

Outcome

Met primary endpoint

registry NUMBER Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027): 0.295 Proportion of participants NCT00307801 ↗

registry Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) vs Placebo; p < 0.0001; inverting 2 one-sided tests NCT00307801 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dienogest Small molecule 3 mg Oral
Subject estradiol valerate Unknown 2 mg Oral

Indications